Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income: 2010-2025

Historic Net Income for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' Net Income fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Net Income is -$16.9 million, which was down 2.02% from -$16.6 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Net Income high stood at -$11.7 million for Q3 2021, and its period low was -$22.5 million during Q2 2022.
  • In the last 3 years, Northwest Biotherapeutics' Net Income had a median value of -$16.9 million in 2024 and averaged -$17.0 million.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Net Income was 78.18% (2021), while the steepest drop was 148.49% (2021).
  • Northwest Biotherapeutics' Net Income (Quarterly) stood at -$11.8 million in 2021, then crashed by 64.00% to -$19.4 million in 2022, then increased by 15.54% to -$16.4 million in 2023, then declined by 28.09% to -$21.0 million in 2024, then dropped by 0.36% to -$16.9 million in 2025.
  • Its last three reported values are -$16.9 million in Q3 2025, -$16.6 million for Q2 2025, and -$18.9 million during Q1 2025.